Surrey Heartlands

Joint Formulary & PAD

Tapentadol hydrochloride - Pain (non-malignant)

You are here : Home > Formulary Search > Tapentadol hydrochloride - Pain (non-malignant)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Modified release tablets
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
CD
R
Restrictions / Comments :
Important
To be prescribed on recommendation from a specialist.

Documentation

Patient resource
Pain management - Prescription agreement (Patient) - May 24
Information
Tapentadol - MHRA drug safety update - January 2019.pdf

PAD Profile

ChemicalSubstance :
Tapentadol hydrochloride
Indication :
Pain (non-malignant)
Group Name :
Keywords :
Opioid analgesia, opioid analgesics
Brand Names Include :
Palexia, Palexia SR, Ationdo SR, Tapimio, Vacicom
Important Information :
Only on recommendation by a pain specialist for patients not responding to / not tolerating morphine or oxycodone
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
2

Other Indications

Below are listed other indications that Tapentadol hydrochloride is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Pain (non-malignant).

  • No records returned.

Committee Recommendations (1)

05 Jun 19 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The APC supports the use of tapentadol SR as a treatment option for the management of severe persistent non-malignant pain in adults after assessment and recommendation by a pain specialist for patients not responding to / not tolerating morphine OR oxycodone.

Due to the similar mode of action and relative efficacy of tapentadol compared with tramadol, it would be appropriate to have tried tramadol before initiating tapentadol.

Tapentadol SR will be considered as BLUE (no information sheet) on the traffic light system. Note added January 2025 - this drug should be prescribed on recommendation from a specialist.

Please be aware of the MHRA drug safety update (January 2019- attached below) in relation to potential increase in seizure risk in patients taking other medicines